Literature DB >> 30293088

The COSMIC Cancer Gene Census: describing genetic dysfunction across all human cancers.

Zbyslaw Sondka1,2, Sally Bamford3, Charlotte G Cole3, Sari A Ward3, Ian Dunham4,5, Simon A Forbes3.   

Abstract

The Catalogue of Somatic Mutations in Cancer (COSMIC) Cancer Gene Census (CGC) is an expert-curated description of the genes driving human cancer that is used as a standard in cancer genetics across basic research, medical reporting and pharmaceutical development. After a major expansion and complete re-evaluation, the 2018 CGC describes in detail the effect of 719 cancer-driving genes. The recent expansion includes functional and mechanistic descriptions of how each gene contributes to disease generation in terms of the key cancer hallmarks and the impact of mutations on gene and protein function. These functional characteristics depict the extraordinary complexity of cancer biology and suggest multiple cancer-related functions for many genes, which are often highly tissue-dependent or tumour stage-dependent. The 2018 CGC encompasses a second tier, describing an expanding list of genes (currently 145) from more recent cancer studies that show supportive but less detailed indications of a role in cancer.

Entities:  

Mesh：

Year:  2018        PMID： 30293088      PMCID： PMC6450507          DOI： 10.1038/s41568-018-0060-1

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  102 in total

1.  Hdac3 is essential for the maintenance of chromatin structure and genome stability.

Authors:  Srividya Bhaskara; Sarah K Knutson; Guochun Jiang; Mahesh B Chandrasekharan; Andrew J Wilson; Siyuan Zheng; Ashwini Yenamandra; Kimberly Locke; Jia-Ling Yuan; Alyssa R Bonine-Summers; Christina E Wells; Jonathan F Kaiser; M Kay Washington; Zhongming Zhao; Florence F Wagner; Zu-Wen Sun; Fen Xia; Edward B Holson; Dineo Khabele; Scott W Hiebert
Journal:  Cancer Cell       Date:  2010-11-16       Impact factor: 31.743

2.  Monoallelic BUB1B mutations and defective mitotic-spindle checkpoint in seven families with premature chromatid separation (PCS) syndrome.

Authors:  Shinya Matsuura; Yoshiyuki Matsumoto; Ken-ichi Morishima; Hideki Izumi; Hiroshi Matsumoto; Emi Ito; Keisuke Tsutsui; Junya Kobayashi; Hiroshi Tauchi; Yoshinori Kajiwara; Seiji Hama; Kaoru Kurisu; Hidetoshi Tahara; Mitsuo Oshimura; Kenshi Komatsu; Tatsuro Ikeuchi; Tadashi Kajii
Journal:  Am J Med Genet A       Date:  2006-02-15       Impact factor: 2.802

Review 3.  The ERCC1 and ERCC4 (XPF) genes and gene products.

Authors:  Mandira Manandhar; Karen S Boulware; Richard D Wood
Journal:  Gene       Date:  2015-06-12       Impact factor: 3.688

Review 4.  ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.

Authors:  Rinath Jeselsohn; Gilles Buchwalter; Carmine De Angelis; Myles Brown; Rachel Schiff
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

5.  Oncogenic role of DDX3 in breast cancer biogenesis.

Authors:  M Botlagunta; F Vesuna; Y Mironchik; A Raman; A Lisok; P Winnard; S Mukadam; P Van Diest; J H Chen; P Farabaugh; A H Patel; V Raman
Journal:  Oncogene       Date:  2008-02-11       Impact factor: 9.867

6.  MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML.

Authors:  Tim Sauer; Maria Francisca Arteaga; Fabienne Isken; Christian Rohde; Katja Hebestreit; Jan-Henrik Mikesch; Matthias Stelljes; Chunhong Cui; Fengbiao Zhou; Stefanie Göllner; Nicole Bäumer; Gabriele Köhler; Utz Krug; Christian Thiede; Gerhard Ehninger; Bayram Edemir; Peter Schlenke; Wolfgang E Berdel; Martin Dugas; Carsten Müller-Tidow
Journal:  Exp Hematol       Date:  2015-06-11       Impact factor: 3.249

7.  Association between cytosolic expression of BRCA1 and metastatic risk in breast cancer.

Authors:  W L Santivasi; H Wang; T Wang; Q Yang; X Mo; E Brogi; B G Haffty; A B Chakravarthy; Fen Xia
Journal:  Br J Cancer       Date:  2015-06-09       Impact factor: 7.640

8.  The significance of dynamin 2 expression for prostate cancer progression, prognostication, and therapeutic targeting.

Authors:  Bin Xu; Liang Hong Teng; Sabrina Daniela da Silva; Krikor Bijian; Samir Al Bashir; Su Jie; Michael Dolph; Moulay A Alaoui-Jamali; Tarek A Bismar
Journal:  Cancer Med       Date:  2013-12-18       Impact factor: 4.452

9.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.

Authors:  David T W Jones; Sylvia Kocialkowski; Lu Liu; Danita M Pearson; L Magnus Bäcklund; Koichi Ichimura; V Peter Collins
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

10.  OncodriveROLE classifies cancer driver genes in loss of function and activating mode of action.

Authors:  Michael P Schroeder; Carlota Rubio-Perez; David Tamborero; Abel Gonzalez-Perez; Nuria Lopez-Bigas
Journal:  Bioinformatics       Date:  2014-09-01       Impact factor: 6.937
View more
  337 in total

1.  Functional Enhancers Shape Extrachromosomal Oncogene Amplifications.

Authors:  Andrew R Morton; Nergiz Dogan-Artun; Zachary J Faber; Graham MacLeod; Cynthia F Bartels; Megan S Piazza; Kevin C Allan; Stephen C Mack; Xiuxing Wang; Ryan C Gimple; Qiulian Wu; Brian P Rubin; Shashirekha Shetty; Stephane Angers; Peter B Dirks; Richard C Sallari; Mathieu Lupien; Jeremy N Rich; Peter C Scacheri
Journal:  Cell       Date:  2019-11-21       Impact factor: 41.582

2.  Fitness variation across subtle environmental perturbations reveals local modularity and global pleiotropy of adaptation.

Authors:  Grant Kinsler; Kerry Geiler-Samerotte; Dmitri A Petrov
Journal:  Elife       Date:  2020-12-02       Impact factor: 8.140

Review 3.  Genetic and non-genetic clonal diversity in cancer evolution.

Authors:  James R M Black; Nicholas McGranahan
Journal:  Nat Rev Cancer       Date:  2021-03-16       Impact factor: 60.716

4.  DNA and RNA sequencing identified a novel oncogene VPS35 in liver hepatocellular carcinoma.

Authors:  Guiji Zhang; Xia Tang; Li Liang; Wanfeng Zhang; Dewei Li; Xiaoyuan Li; Dachun Zhao; Yaqiu Zheng; Yanhong Chen; Bingtao Hao; Kai Wang; Ni Tang; Keyue Ding
Journal:  Oncogene       Date:  2020-02-19       Impact factor: 9.867

5.  An atlas of transposable element-derived alternative splicing in cancer.

Authors:  Evan A Clayton; Lavanya Rishishwar; Tzu-Chuan Huang; Saurabh Gulati; Dongjo Ban; John F McDonald; I King Jordan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2020-02-10       Impact factor: 6.237

6.  Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features.

Authors:  Rémi Buisson; Adam Langenbucher; Danae Bowen; Eugene E Kwan; Cyril H Benes; Lee Zou; Michael S Lawrence
Journal:  Science       Date:  2019-06-28       Impact factor: 47.728

7.  Cancer mutational burden is shaped by G4 DNA, replication stress and mitochondrial dysfunction.

Authors:  Albino Bacolla; Zu Ye; Zamal Ahmed; John A Tainer
Journal:  Prog Biophys Mol Biol       Date:  2019-03-14       Impact factor: 3.667

8.  Profiling the Mutational Landscape in Known Driver Genes and Novel Genes in African American Non-Small Cell Lung Cancer Patients.

Authors:  Christine M Lusk; Donovan Watza; Greg Dyson; Douglas Craig; Valerie Ratliff; Angela S Wenzlaff; Fulvio Lonardo; Aliccia Bollig-Fischer; Gerold Bepler; Kristen Purrington; Shirish Gadgeel; Ann G Schwartz
Journal:  Clin Cancer Res       Date:  2019-04-12       Impact factor: 12.531

9.  e-MutPath: computational modeling reveals the functional landscape of genetic mutations rewiring interactome networks.

Authors:  Yongsheng Li; Brandon Burgman; Ishaani S Khatri; Sairahul R Pentaparthi; Zhe Su; Daniel J McGrail; Yang Li; Erxi Wu; S Gail Eckhardt; Nidhi Sahni; S Stephen Yi
Journal:  Nucleic Acids Res       Date:  2021-01-11       Impact factor: 16.971

10.  A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.

Authors:  Nikhil Wagle; Rachel A Freedman; Sara M Balch; Ines Vaz-Luis; Tianyu Li; Nabihah Tayob; Esha Jain; Karla Helvie; Jorge E Buendia-Buendia; Erin Shannon; Steven J Isakoff; Nadine M Tung; Ian E Krop; Nancy U Lin
Journal:  Breast Cancer Res Treat       Date:  2021-07-24       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.